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Summary In a multicentre study, 83 patients with advanced and previously uniformly treated multiple
myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2),
administered every 3 weeks for three courses and both associated with prednisone and interferon-a2b. Both
regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were
similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively)
compare well with those obtained with more aggressive chemotherapy schedules.
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Treatment of advanced multiple myeloma (MM) usually
employs combination chemotherapy (Buzaid and Durie,
1988). We used either cyclophosphamide (CTX) or epirubi-
cin (EPI), both associated with recombinant interferon (IFN)
and prednisone (P), as third-line therapy, with the expectancy
that haematological toxicity would be low and the therapy
feasible on an outpatient basis. All patients came from
Protocol MM87 (Riccardi et al., 1994), where they were
treated, as first-line therapy, either with melphalan and
prednisone (MPH -P) or peptichemio (PTC), vincristine
(VCR) and P. As second-line therapy, patients resistant to
or relapsed following one combination were crossed to the
other combination.
The choice of salvage CTX came from the fact that MPH-
resistant MM patients may respond to this drug (Bergsagel et
al., 1972; Lenhard et al., 1984). The use of EPI was justified
by the response of advanced patients to the several
combination chemotherapies including anthracycline (Al-
berts et al., 1976; Finnish Leukaemia Group, 1990).
Materials and methods
Between January 1989 and December 1993, 83 consecutive
patients (Table I) entered a third-line, prospective, multi-
centre, randomised protocol (Protocol MM87/01) for
advanced MM. Patients were primarily resistant to or
relapsed following a response to first- and second-line
therapies of Protocol MM87 (i.e. to MPH-P and PTC-
VCR-P) (Riccardi et al., 1994).
Randomisation was between EPI (70 mg m-2) and CTX
(600 mg m-2) given by i.v. infusion on day 1 every 3 weeks
for 3 courses. Both cytostatics were combined with P
(2mgkg-l day-', days 1-4 and 11-15) and IFN-a2b
(3 MU three times a week).
Response, maintenance therapy and relapse
Response was evaluated at the end of induction therapy,
according to slightly modified clinical criteria (Riccardi et al.,
1994) adopted by the SECSG (Cohen et al., 1979).
Responsive patients continued therapy until maximum
reduction in monoclonal component (MC) (i.e. the plateau
phase) was reached and maintained for 6 months, with stable
clinical, haematological and radiological conditions. Then,
they continued only on IFN-o2b (3 MU three times a week)
as a maintenance therapy.
Relapse was defined as a >50% increase in the plateau
level of MC and/or an increase in the size and/or number of
skeletal lytic lesions.
Follow-up and statistical evaluation
The guidelines for following up MM are similar to those
detailed elsewhere (Riccardi et al., 1994). To define the drug
toxicity blood counts were performed twice in the interval
between courses.
The statistical evaluation ofthe differences in response rate
and duration of response (from the end of successful
induction therapy until relapse) and of survival (from
randomisation to death) are described elsewhere (Riccardi
et al., 1994).
Results
In both EPI-P-IFN and CTX-P-IFN arms, patients were
similar for the main clinical characteristics (Table I), and
more of them had received MPH-P as a first-line therapy,
with similar response rate.
Patients who relapsed following a response to first-line
therapy had received a median of 19.8 (range 12-33) and of
17.1 (10-28) courses of MPH-P and PTC-VCR-P
respectively. In patients who were primarily resistant, the
corresponding figures were 12.1 (10-16) and 12.4 (8-16).
Response
Response was evaluated in 70/83 (85%) patients (Table II),
including four patients (two from each arm) who died before
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Table I Main clinical characteristics of patients with advanced multiple myeloma who were randomised to be treated, as third-line therapy,
with the combination of epirubicin, prednisone and recombinant interferon-a2b (EPI-P-IFN) or with the combination of cyclophosphamide,
prednisone and recombinant interferon-a2b (CTX-P-IFN)
EPI-P-IFN CTX-P-IFN Overall
Number of patients 43 40 83
Male/Female 21/22 20/20 41/42
Median age (years) (range) 58 (46-75) 62 (44-79) 61 (0-79)
IgG 35 25 60
IgA 7 12 19
LC 1 3 4
K 26 25 51
L 17 15 32
f-2 jigml-1, median (range) 5.1 (1.4-13.7) 4.8 (2.1-11.3) 4.9 (1.4-13.7)
Lytic lesions
0-3 (%) 6 (14) 9 (22) 15 (18)
>3 ()8 (19) 5 (13) 13 (16)
with pathological
fractures (%) 29 (67) 26 (65) 55 (66)
Hb, gdl2
>9 30 26 56
(9 13 14 27
Serum creatinine, mgdl-'
(2 41 39 80
>2 2 1 3
Prior first-line therapy
MPH-P, no. of patients 30 33 63
PR+CR (%) 34 40 37
NR (%) 66 60 63
PTC-VCR-P, no. of patients 13 7 20
PR+CR (%) 54 43 50
NR (%) 46 57 50
MPH-P, melphalan-prednisone; PTC-VCR-P, peptichemio-
response (stable + progressive disease).
-vincristine-prednisone; PR, partial response; CR, complete response; NR, no
Table H Response of patients with advanced multiple myeloma to the combination of epirubicin, prednisone and recombinant interferon-a2b
(EPI-P-IFN) or to the combination of cyclophosphamide, prednisone and recombinant interferon-oc2b (CTX-P-IFN)
EPI-P-IFN CTX-P-IFN Overall
Evaluable patients 37 33 70
Relapsed patientsa 14 13 27
Resistant patientsb 23 20 43
CR+PR (%) 14/37 (38) 16/33 (48) 30/70 (43)
In relapsed patients (%)b 4/14 (28) 6/13 (46) 10/27 (37)
In resistant patients (%)" 10/23 (43) 10/20 (50) 20/43 (47)
PR (%) 8/37 (22) 13/33 (40) 21/70 (30)
CR (%) 6/37 (16) 3/33 (8) 9/70 (12)
SD (%) 16/37 (43) 13/33 (40) 29/70 (42)
PD (%) 7/37 (19) 4/33 (12) 11/70 (16)
aRelapsed patients are those patients who relapsed following a response to first-line therapy with MPH-P or withPTC-VCR-P. bResistant
patients are those patients who were primarily resistant to both MPH-P and PTC-VCR-P as first- and second-line therapies. PD, progressive
disease (other abbreviations as in Table I)
response could be established and were considered as non-
responders. Thirteen patients were not evaluated for refusal
to continue treatment (four patients), insufficient data or lost
to follow-up (nine patients).
The overall response rate was 43%, without statistical
difference between the EPI-P-IFN (38%) and the CTX-
P-IFN (48%) arm.
The response rate was similar in patients firstly treated
with MPH-P and with PTC-VCR-P.
More responsive patients had WHO/ECOG performance
status ameliorated (Table III), in a median time of 7 (range:
6-10) weeks in the EPI-P-IFN and of 10 (range: 6-12)
weeks in the CTX-P-IFN arm.
Duration of response and of survival
The overall median duration of response was 5.9 months. It
was similar in the EPI-P-IFN (5.5 months) and in the
CTX-P-IFN (6.4 months) arm.
Table m Changes in WHO/ECOG performance status in
responder patients with advanced multiple myeloma treated with
third-line therapy (EPI-P-IFN or CTX-P-IFN)
WHO/ECOG No. ofpatients
performance status Before therapy After therapy
EPI-P-IFN arm (A)
0-1 4 11
2 4 3
3 6 1
CTX-P-IFN arm (B)
0-1 6 7
2 5 6
3 5 3
Arm A+Arm B
0-1 10 18
2 9 9
3 11 4
(abbreviations as in Table I)
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Fugwe 1 Duration of survival in MM patients who were
randomised to be treated for third-line therapy with the
combination of epirubicin, predisone and interferon-a2b (EPI-
P-IFN) ( ) (33 patients, 13 censored) or with the
combination of cyclophosphamide, prednisone and interferon-
a2b (CTX-P-IFN) --- - -) (30 patients, 17 censored). P-value,
not significant.
Overall median survival was 14.1 months. It was similar in
the EPI-P-IFN (13.9 months) and in the CTX-P-IFN
(14.3 months) arm (Figure 1), as well as in patients who were
primarily resistant to first-line therapy (15.0 months) and in
those who relapsed following a response (13.4 months).
Toxicity
Overall haematological toxicity was low and 88% of courses
were administered on an outpatient basis.
Febrile neutropenia occurred in 12% and grade Ill
anaemia and thrombocytopenia in 7% and 5% of patients.
These figures were somewhat but not significantly greater in
the EPI-P-IFN than in the CTX-P-IFN arm (15%, 10%
and 7% vs 6%, 4% and 2% respectively).
Grade 2-3 alopecia was distinctly more frequent in the
EPI-P-IFN than in the CIX-P-IFN (55% vs 9%,
P<0.01). Grade 2 emesis occurred in 20% and 9% (P-
value not significant) of patients respectively. Stomatitis was
unusual.
Four patients in both arms stopped IFN for grade 3 chills
and/or fever, uncontrolled by acetaminophen premedications.
There was no cardiac damag attributable to EPI and no
gastrointestinal, psychiatric or metabolic damage attributable
to steroids.
In this randomised study, patients with MM who were
resistant to or relapsed following MPH-P and PTC-VCR-
P achieved similar clinical benefit from being treated with
EPI-P-IFN or CTX-P-IFN. In fact, response rate,
changes in WHO/ECOG status and response and survival
duration were similar with the two regimens.
These results are in keeping with published data on the
value of CTX and anthracyclines for advanced MM. Used
alone, CTX was effective in a number (Bersagel et al., 1972;
Brandes and Israels, 1987), although not in all (Presant and
Klahr, 1978; Maclennan and Cuzick, 1985), non-randomised
investigations. At present it is incorporated into regimens for
refractory disease (Kyle et al., 1975; Steinke et al., 1985).
Anthracyclines have not been used as a single agent.
However, anthracycline-containing rgmens are effective in
both relapsed (Alexanian and Deeicer, 1984; Barlogie and
Alexanian, 1987; Presant and Klahr, 1978) and primarily
resistant (Cornelissen et al., 1994) patients. The clinical role
of IFN and steroids in favouring the effectiveness of both
EPI and CTX cannot be established in this study.
As expected, haematological toxicity was low, non-
haematological toxicity was acceptable and most patients
were treated on an outpatient basis.
The overall 14.1 month median survival compares well
with the median survivals of 5-22 months (the weighted
median is about 10 months) reported in small non-
randomised studies on salvage therapy in MM (Bonnet et
al., 1984; Lenhard et al., 1984; Steinke et al., 1985; Alexanian
et al., 1986; Forgeson et al., 1988; Finnish Leukaemia Group,
1990; Friedenberg et al., 1991; Gimsing et al., 1991;
Cornelissen et al., 1994). These usually employed more
cytotoxic drug combinations and often required hospitalisa-
tion. Median survival is also not better in young patients with
advanced disease following autologous bone marrow (BM) or
peripheral blood stem cell transplantation (Barlogie et al.,
1986; Fermand et al., 1989).
In conclusion, it seems clinically acceptable to treat
advanced MM with poorly myelosuppressive regimens based
on medium doses of CIX or anthracyclines.
The following centres also participated in this study:
Servizio di Oncologia, Ospedale S. Anna, 22100 Como (Dr C
Epifani, Dr M Giordano); Divisione di Ematologia, Ospedale
di Pesaro, 61100 Pesaro (Dr C Delfini); Medicina I, Ospedale
di Alessandria (Dr G Montanaro, Dr A Pagetto); Medicina I,
Ospedale di Melegnano (Professor G Santagati, Dr L Dezza);
Medicina I, Ospedale di Gallarate (Dr A Ceriani, Dr R
Castiglioni); Cattedra di Ematologia, Universiti di Parma
(Professor V Rizzoli, Dr G Dotti); Medicina B, Ospedale di
Biella (Professor S Fontana, Dr M Badone); Medicina
Generale, Ospedale di Somma Lombardo (Professor M
Mainardi, Dr A Daverio); Medicina C, Ospedale di Varese
(Dr N Brumana); Medicina A, Ospedale di Varese (Dr G
Pinotti).
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